Nazila Habibizad - 27 Sep 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role
Executive Vice President, Operations
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
27 Sep 2022
Net transactions value
+$570,391
Form type
4
Filing time
29 Sep 2022, 20:47:43 UTC
Previous filing
06 Sep 2022
Next filing
04 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise $305,581 +23,597 +199% $12.95* 35,465 27 Sep 2022 Direct
transaction GBT Common Stock Options Exercise $89,399 +3,005 +8.5% $29.75 38,470 27 Sep 2022 Direct
transaction GBT Common Stock Options Exercise $121,763 +2,043 +5.3% $59.60 40,513 27 Sep 2022 Direct
transaction GBT Common Stock Options Exercise $49,748 +1,027 +2.5% $48.44 41,540 27 Sep 2022 Direct
transaction GBT Common Stock Options Exercise $3,900 +83 +0.2% $46.99 41,623 27 Sep 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Stock Option (Right to Buy) Options Exercise $0 -23,597 -100% $0.000000* 0 27 Sep 2022 Common Stock 23,597 $12.95 Direct F1
transaction GBT Stock Option (Right to Buy) Options Exercise $0 -3,005 -33% $0.000000 5,995 27 Sep 2022 Common Stock 3,005 $29.75 Direct F2
transaction GBT Stock Option (Right to Buy) Options Exercise $0 -2,043 -26% $0.000000 5,957 27 Sep 2022 Common Stock 2,043 $59.60 Direct F3
transaction GBT Stock Option (Right to Buy) Options Exercise $0 -1,027 -19% $0.000000 4,448 27 Sep 2022 Common Stock 1,027 $48.44 Direct F4
transaction GBT Stock Option (Right to Buy) Options Exercise $0 -83 -1% $0.000000 7,917 27 Sep 2022 Common Stock 83 $46.99 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Common Stock underlying the stock option vested as to 25% of the original grant for 30,000 shares on January 11, 2017 and in 12 equal quarterly installments thereafter through January 11, 2020.
F2 The shares of Common Stock underlying the stock option vested in 16 quarterly installments from March 1, 2017 through March 1, 2021.
F3 The shares of Common Stock underlying the stock option vested in 16 quarterly installments from February 1, 2018 through February 1, 2022.
F4 The shares of Common Stock underlying the stock option vest in 16 quarterly installments from February 1, 2019 through February 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F5 The shares of Common Stock underlying the stock option vest in 16 quarterly installments from October 1, 2019 through October 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

Executive Vice President, Operations